Ingelheim, 24 April 2012 – The pharmaceutical company Boehringer Ingelheim is well-equipped for the future. In the 2011 financial year, net sales, after currency adjustment, increased by 6.2 % to EUR 13.2 billion. At the same time, operating income rose to EUR 2.3 billion and the return on net sales increased to 17.3 %. As already announced in previous years, the company has thereby successfully realised its plans – including mid-single figure growth. "The 2011 results confirm our strategy of organic growth", said Professor Andreas Barner, Chairman of the Board of Managing Directors with responsibility for Research & Development and Medicine, in conjunction with the annual press conference at the corporate headquarters in Ingelheim, Germany. With its own highly competitive research, Boehringer Ingelheim is successfully and sustainably ensuring its independence as a family-owned company. "Thanks to our continued investment in our own research and development, we are starting a new period of growth", according to Prof. Barner.